EHA 2023 | Efficacy of varnimcabtagene autoleucel in patients with R/R BCL with no indication for CAR-T therapy
Valentín Ortiz-Maldonado, MD, Hospital Clinic de Barcelona, Barcelona, Spain, discusses a study evaluating the compassionate use of varnimcabtagene autoleucel (var-cel; ARI-0001) in patients with relapsed/refractory (R/R) B-cell lymphomas (BCL) with no approved treatment options and with no indications for standard of care (SOC) commercial CAR-T therapies. The study reported a high complete response rate and low relapse rate after achieving complete remission, thereby suggesting this CAR-T therapy can rescue these patients with few treatment options. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
